Literature DB >> 18985344

Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.

Reiko Kameyama1, Yuka Yamamoto, Kunihiko Izuishi, Ryusuke Takebayashi, Masanobu Hagiike, Makiko Murota, Masato Kaji, Reiji Haba, Yoshihiro Nishiyama.   

Abstract

PURPOSE: We prospectively investigated the feasibility of 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography (PET) for the detection of gastric cancer, in comparison with 2-deoxy-2-(18)F-fluoro-D-glucose (FDG) PET, and determined the degree of correlation between the two radiotracers and proliferative activity as indicated by Ki-67 index.
METHODS: A total of 21 patients with newly diagnosed advanced gastric cancer were examined with FLT PET and FDG PET. Tumour lesions were identified as areas of focally increased uptake, exceeding that of surrounding normal tissue. For semiquantitative analysis, the maximal standardized uptake value (SUV) was calculated.
RESULTS: For detection of advanced gastric cancer, the sensitivities of FLT PET and FDG PET were 95.2% and 95.0%, respectively. The mean (+/-SD) SUV for FLT (7.0 +/- 3.3) was significantly lower than that for FDG (9.4 +/- 6.3 p < 0.05). The mean FLT SUV and FDG SUV in nonintestinal tumours were higher than in intestinal tumours, although the difference was not statistically significant. The mean (+/-SD) FLT SUV in poorly differentiated tumours (8.5 +/- 3.5) was significantly higher than that in well and moderately differentiated tumours (5.3 +/- 2.1; p < 0.04). The mean FDG SUV in poorly differentiated tumours was higher than in well and moderately differentiated tumours, although the difference was not statistically significant. There was no significant correlation between Ki-67 index and either FLT SUV or FDG SUV.
CONCLUSION: FLT PET showed as high a sensitivity as FDG PET for the detection of gastric cancer, although uptake of FLT in gastric cancer was significantly lower than that of FDG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985344     DOI: 10.1007/s00259-008-0970-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs.

Authors:  Jeffrey L Schwartz; Yasuko Tamura; Robert Jordan; John R Grierson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

2.  The role of 18F-FLT in cancer imaging: does it really reflect proliferation?

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 3.  Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.

Authors:  Frédérique Spyratos; Magali Ferrero-Poüs; Martine Trassard; Kamel Hacène; Edelmira Phillips; Michèle Tubiana-Hulin; Viviane Le Doussal
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

Review 4.  Whole-body FDG-PET imaging in the management of patients with cancer.

Authors:  Roland Hustinx; François Bénard; Abass Alavi
Journal:  Semin Nucl Med       Date:  2002-01       Impact factor: 4.446

5.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.

Authors:  D L Francis; D Visvikis; D C Costa; T H A Arulampalam; C Townsend; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

6.  Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study.

Authors:  Katja Ott; Ken Herrmann; Florian Lordick; Hinrich Wieder; Wolfgang A Weber; Karen Becker; Andreas K Buck; Martin Dobritz; Ulrich Fink; Kurt Ulm; Tibor Schuster; Markus Schwaiger; Jörg-Rüdiger Siewert; Bernd J Krause
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

7.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.

Authors:  D L Francis; A Freeman; D Visvikis; D C Costa; S K Luthra; M Novelli; I Taylor; P J Ell
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

8.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.

Authors:  Andreas K Buck; Gisela Halter; Holger Schirrmeister; Jörg Kotzerke; Imke Wurziger; Gerhard Glatting; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske; Martin Hetzel
Journal:  J Nucl Med       Date:  2003-09       Impact factor: 10.057

9.  Human thymidine kinase 1. Regulation in normal and malignant cells.

Authors:  B Munch-Petersen; L Cloos; H K Jensen; G Tyrsted
Journal:  Adv Enzyme Regul       Date:  1995

10.  18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.

Authors:  David C P Cobben; Bernard F A M van der Laan; Bram Maas; Willem Vaalburg; Albert J H Suurmeijer; Harald J Hoekstra; Pieter L Jager; Philip H Elsinga
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

View more
  21 in total

Review 1.  Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT.

Authors:  Mijin Yun
Journal:  J Gastric Cancer       Date:  2014-03-31       Impact factor: 3.720

Review 2.  Preoperative staging of nodal status in gastric cancer.

Authors:  Felix Berlth; Seung-Hun Chon; Mickael Chevallay; Minoa Karin Jung; Stefan Paul Mönig
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-07

3.  Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Yuko Goto; Megumi Jinguji; Sadao Tanaka; Yoshihiko Fukukura; Atsushi Tani; Michiyo Higashi
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

Review 4.  Gastric cancer: surgery in 2011.

Authors:  Katja Ott; Florian Lordick; Susanne Blank; Markus Büchler
Journal:  Langenbecks Arch Surg       Date:  2011-01-14       Impact factor: 3.445

Review 5.  Diagnosis and evaluation of gastric cancer by positron emission tomography.

Authors:  Chen-Xi Wu; Zhao-Hui Zhu
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

6.  Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.

Authors:  Yoshitaka Honma; Takashi Terauchi; Ukihide Tateishi; Daisuke Kano; Kengo Nagashima; Hirokazu Shoji; Satoru Iwasa; Atsuo Takashima; Ken Kato; Tetsuya Hamaguchi; Narikazu Boku; Yasuhiro Shimada; Yasuhide Yamada
Journal:  Br J Radiol       Date:  2018-06-27       Impact factor: 3.039

7.  Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers.

Authors:  Hiroshi Hoshikawa; Yoshihiro Nishiyama; Takehito Kishino; Yuka Yamamoto; Reiji Haba; Nozomu Mori
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

8.  Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice.

Authors:  Hui Wang; Bo Liu; Jia-He Tian; Bai-Xuan Xu; Zhi-Wei Guan; Bao-Lin Qu; Chang-Bin Liu; Rui-Min Wang; Ying-Mao Chen; Jin-Ming Zhang
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

9.  Assessment of cellular proliferation in tumors by PET using 18F-ISO-1.

Authors:  Farrokh Dehdashti; Richard Laforest; Feng Gao; Kooresh I Shoghi; Rebecca L Aft; Brian Nussenbaum; Friederike H Kreisel; Nancy L Bartlett; Amanda Cashen; Nina Wagner-Johnston; Nina Wagner-Johnson; Robert H Mach
Journal:  J Nucl Med       Date:  2013-01-28       Impact factor: 10.057

10.  Assessment of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer.

Authors:  Tsutomu Namikawa; Takehiro Okabayshi; Munenobu Nogami; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Int J Clin Oncol       Date:  2013-07-24       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.